Stay updated on Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.

Latest updates to the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page
- Check3 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check39 days agoChange DetectedDifference0.3%
- Check46 days agoChange DetectedThe web page has undergone significant content removal, including the detailed description of a Phase 1/2 study evaluating Loncastuximab Tesirine and Ibrutinib for lymphoma treatment, which is critical information for potential participants and stakeholders. Additionally, the revision number has been updated from v2.14.4 to v2.15.0.SummaryDifference25%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check61 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
Stay in the know with updates to Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lonca Tesirine + Ibrutinib in Lymphoma Clinical Trial page.